StockDecksEli Lilly and vs Merck & Co.
Eli Lilly and Company (LLY) and Merck & Co., Inc. (MRK) · Healthcare
As of 24 October 2026, Eli Lilly and has a StockDecks Fundamental Score of +26 (grade B+) and Merck & Co. −6 (grade C), on a −100 to +100 scale. Eli Lilly and rates higher on Profitability and Growth; Merck & Co. rates higher on Financial Health and Valuation.
| Rating | LLY | MRK |
|---|---|---|
| Fundamental Score | +26Grade B+ | -6Grade C |
| Financial Health | +6 | +15 |
| Profitability | +66 | -13 |
| Growth | +82 | +1 |
| Valuation | -50 | -29 |
Both companies are measured against the same Healthcare benchmarks, so their scores compare directly. Scores describe each company as it stands; they are not forecasts or recommendations.
The measures side by side
Each figure is the latest reported value; the number beneath is how it scores on the −100 to +100 scale. A dash means no genuine figure is available. Tap a measure’s name for a plain-English explanation.
Financial Health
| Measure | LLY | MRK |
|---|---|---|
| Debt to equity | 1.62×-28 | 1.28×-13 |
| Current ratio | 1.36×+32 | 1.32×+29 |
| Quick ratio | 0.68×-22 | 0.74×-10 |
| FCF / Total debt | 0.2×+13 | 0.28×+34 |
Profitability
| Measure | LLY | MRK |
|---|---|---|
| Gross margin | 83.4%+94 | 75.9%+92 |
| Operating margin | 54.2%+98 | -0.2%-93 |
| Net margin | 33.5%+96 | 4.8%-67 |
| Return on equity | 102.3%+100 | 7%-27 |
| Gross profit / assets | 48.1%+54 | 35.5%+31 |
| Asset turnover | 0.58× | 0.47× |
Growth
| Measure | LLY | MRK |
|---|---|---|
| Revenue growth (YoY) | 47.7%+98 | 5.1%+1 |
| Earnings growth (YoY) | 26.2%+76 | — |
| Earnings growth (Q) | 25.3%+73 | — |
Valuation
| Measure | LLY | MRK |
|---|---|---|
| P/E (trailing) | 42.75×-46 | 115.29×-97 |
| Forward P/E | 26.97×-21 | 15.73×+48 |
| PEG ratio | 1.26×+31 | 2.75×-75 |
| Price/Book | 33.51×-100 | 8.55×-91 |
| Price/Sales | 14.25×-83 | 5.38×-3 |
| EV/EBITDA | 28.32×-60 | 14.04×+12 |
| FCF yield | 1%-68 | 4.2%+3 |
Key figures
| LLY | MRK | |
|---|---|---|
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Market cap | $1.14T | $358.4B |
| Dividend yield | 0.54% | 2.34% |
| Payout ratio | 21.69% | 266.67% |
| Beta | 0.45 | 0.22 |
About the companies
Eli Lilly and. Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. Full Eli Lilly and rating
Merck & Co.. Merck & Co., Inc. operates as a healthcare company worldwide. Full Merck & Co. rating
See the live cards
These figures were captured on 24 October 2026. StockDecks shows the current numbers, plus Hype, Analyst Upside, Trend Signals and Insider Track, all free.